Association between hematological biomarkers and response on the
first CT scan
In univariate analysis, higher levels of NLR2 and PLR2 were associated
with a decreased likelihood of being a P vs an HP (OR, 0.67; 95% CI,
0.53-0.86; p=0.001; OR, 0.993; 95% CI, 0.98-0.99; p=0.006,
respectively). On univariate analysis, higher levels of NLR2, PLR2 and
∆PLR were associated with a decreased likelihood of being an NP vs an HP
(OR, 0.61; 95% CI, 0.48-0.76; p<0.0001; OR, 0.991; 95% CI,
0.98-0.99; p<0.0001, OR, 0.994; 95% CI, 0.98-0.99; p=0.008,
respectively). After adjustment for age, sex, PD-L1 expression and
number of metastatic sites, higher levels of NLR2 were associated with a
decreased likelihood of being an NP vs an HP (OR, 0.44; 95% CI,
0.28-0.69; p<0.0001) and showed a trend for being associated
with a decreased likelihood of being a P vs an HP (OR, 0.66; 95% CI,
0.42-1.06; p=0.09) (Table 4).
Overall survival of HPs, PPs, Ps, NPs and patients with
sarcopenia
HPs at the first CT evaluation had a significantly shorter mean OS (9.83
months; 95%, CI 8.44-11.22) than PPs (19.18 months; 95%, CI
14.13-24.22) (log-rank test p=0.001), Ps (17.32 months; 95%, CI
15.67-18.98) (log-rank test p<0.001) and NPs (29.79 months;
95%, CI 26.87-32.71) (log-rank test p<0.001) (Figure 2A).
Patients with sarcopenia had a significantly shorter mean OS (13.5
months; 95%, CI 11.7-15.2) than patients without sarcopenia (31.5
months; 95%, CI 27.6-35.8) (log-rank test p<0.001) (Figure
2B).